RZLT Insider Trading

Insider Ownership Percentage: 18.39%
Insider Buying (Last 12 Months): $425,506.35
Insider Selling (Last 12 Months): $0.00

Rezolute Insider Trading History Chart

This chart shows the insider buying and selling history at Rezolute by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$47kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k$0$200kTotal Insider BuyingTotal Insider Selling

Rezolute Share Price & Price History

Current Price: $3.85
Price Change: Price Decrease of -0.02 (-0.52%)
As of 03/7/2025 05:00 PM ET

This chart shows the closing price history over time for RZLT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$3.85Closing price on 03/09/25:

SEC Filings (Institutional Ownership Changes) for Rezolute (NASDAQ:RZLT)

82.97% of Rezolute stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RZLT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$24Mbought$5.94MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal InflowsTotal Outflows
Rezolute logo
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Read More on Rezolute

Today's Range

Now: $3.85
Low: $3.68
High: $3.88

50 Day Range

MA: $4.77
Low: $3.85
High: $5.57

52 Week Range

Now: $3.85
Low: $1.66
High: $6.19

Volume

299,823 shs

Average Volume

452,640 shs

Market Capitalization

$233.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Who are the company insiders with the largest holdings of Rezolute?

Rezolute's top insider shareholders include:
  1. Daron Evans (CFO)
  2. Young-Jin Kim (Director)
  3. Wladimir Hogenhuis (Director)
  4. Brian Kenneth Roberts (Insider)
  5. Nevan C Elam (CEO)
Learn More about top insider investors at Rezolute.

Who are the major institutional investors of Rezolute?

Rezolute's top institutional shareholders include:
  1. Nantahala Capital Management LLC — 4.93%
  2. Adage Capital Partners GP L.L.C. — 4.36%
  3. Altium Capital Management LLC — 2.92%
  4. Affinity Asset Advisors LLC — 2.72%
  5. ADAR1 Capital Management LLC — 2.35%
  6. Sphera Funds Management LTD. — 2.01%
Learn More about top institutional investors of Rezolute stock.

Which institutional investors are selling Rezolute stock?

During the last quarter, RZLT stock was sold by these institutional investors:
  1. Marshall Wace LLP
  2. Schonfeld Strategic Advisors LLC
  3. Bank of America Corp DE
  4. ADAR1 Capital Management LLC
  5. Renaissance Technologies LLC
  6. Affinity Asset Advisors LLC
  7. Cubist Systematic Strategies LLC
  8. Sphera Funds Management LTD.

Which institutional investors are buying Rezolute stock?

In the previous quarter, RZLT stock was bought by institutional investors including:
  1. Adage Capital Partners GP L.L.C.
  2. Woodline Partners LP
  3. Susquehanna International Group LLP
  4. Walleye Capital LLC
  5. Nantahala Capital Management LLC
  6. Integral Health Asset Management LLC
  7. J. Goldman & Co LP
  8. Point72 Europe London LLP
During the last year, these company insiders have bought Rezolute stock:
  1. Daron Evans (CFO)
  2. Young-Jin Kim (Director)
  3. Wladimir Hogenhuis (Director)
  4. Brian Kenneth Roberts (Insider)
  5. Nevan C Elam (CEO)
Learn More investors buying Rezolute stock.